Rate My Professor Monika Janda

Professor Monika Janda is Professor in Behavioural Science at the Faculty of Health, Medicine & Behavioural Sciences, University of Queensland. She serves as Deputy Director of the Frazer Institute and is an NHMRC Leadership Fellow for the period 2025 to 2029. Professor Janda leads the NHMRC Centre of Research Excellence in Skin Imaging and Precision Diagnosis and the NHMRC-funded Synergy Roadmap Towards Melanoma Screening. She trained as a health and clinical psychologist and is a behavioural scientist whose research focuses on cancer prevention, particularly melanoma, quality of life research, and consumer-centred digital interventions to support self-management of health issues. Her work emphasises applied health and clinical research to improve cancer prevention, early detection, and treatment outcomes, with strong clinical collaborations. Previously, until 2017, she led the Health Determinants and Health Systems Theme at the Institute of Health and Biomedical Innovation at Queensland University of Technology. Her research has been supported by multiple NHMRC fellowships, including a Translating Research into Practice Fellowship, Career Development Fellowships, and an Early Career Fellowship. Professor Janda contributed to trials such as the LACE and feMMe trials, which influenced standard treatment for early-stage endometrial cancer, and she has developed quality of life assessment tools used internationally. Her research has informed more than 30 clinical practice guidelines and over 20 international policy documents, with impacts on skin cancer prevention targets in Queensland. She has supervised numerous postgraduate students to completion.

Professor Janda’s primary research interests include melanoma prevention and early detection, quality of life interventions for cancer patients, and the use of mobile and digital technologies to improve health behaviours. She has a strong focus on behavioural and clinical trials that test digital and behavioural interventions, leading to changes in prevention, treatment, and supportive care, as well as cost-effective outcomes. Her contributions to behavioural oncology have advanced preventive and clinical care delivery through innovative methods of health services delivery and policy influence.